Atopic Dermatitis

>

Latest News

Lawrence Eichenfield, MD, Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics
Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis

October 7th 2025

A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children 2 to 5 years.

FDA approves roflumilast cream 0.05% for atopic dermatitis for children 2 to 5 years | Image credit: Contemporary Pediatrics
FDA approves roflumilast cream 0.05% for atopic dermatitis for children aged 2 to 5 years

October 6th 2025

5 pediatric FDA decisions to watch for in Q4 2025 | Image credit: Contemporary Pediatrics
Key pediatric FDA decisions to watch for in Q4 2025

September 30th 2025

Phase 2b study: Rezpegaldesleukin demonstrates efficacy in atopic dermatitis patients | Image Credit: © Марина Терехова - stock.adobe.com.
Phase 2b study: Rezpegaldesleukin demonstrates efficacy in atopic dermatitis patients

September 19th 2025

FDA approves ruxolitinib for pediatric atopic dermatitis | Image Credit: Contemporary Pediatrics
FDA approves ruxolitinib for pediatric patients with atopic dermatitis aged 2 to 11 years

September 18th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.